RCC
Welireg Approved for Advanced Renal Cell Carcinoma
The FDA approved belzutifan (Welireg, Merck) for patients with advanced renal cell carcinoma (RCC) following a ...
DECEMBER 15, 2023
Keytruda Gains Approval to Treat Patients With RCC After Nephrectomy
The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma ...
NOVEMBER 29, 2021
Lenvima Plus Keytruda Approved for First-Line Treatment of Advanced RCC
The FDA approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) for first-line ...
AUGUST 16, 2021
FDA Approves Tivozanib for Adult Patients With Relapsed or Refractory Advanced RCC
The FDA approved tivozanib (Fotivda, AVEO Oncology) for the treatment of adults with relapsed or refractory ...
MARCH 12, 2021
FDA Approves Nivolumab-Cabozantinib as First-Line Treatment of Advanced RCC
The FDA approved nivolumab in combination with cabozantinib for the first-line treatment of patients with advanced ...
FEBRUARY 15, 2021
CheckMate 9ER Trial: ICI Provides Survival Benefit in Renal Cell Carcinoma
Relative to the previous standard of sunitinib, a combination of the checkpoint inhibitor nivolumab and the ...
DECEMBER 4, 2020
New Definition of Local Recurrence for Renal Cell Carcinoma
Researchers have laid out a novel definition of local recurrence in patients with higher-risk nonmetastatic renal ...
APRIL 6, 2020
Keytruda Gains 2 New First-Line Indications: NSCLC and RCC
The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III/IV ...
APRIL 24, 2019
First-Line Avelumab-Axitinib Combo Increases PFS for Patients With Advanced RCC
First-line treatment combining the immune checkpoint blocker avelumab (Bavencio, EMD Serono/Pfizer) with the ...
JANUARY 24, 2019
Atezolizumab With Bevacizumab Ups PFS in PD-L1-Positive Advanced RCC Patients
First-line treatment with atezolizumab plus bevacizumab results in better PFS in programmed death-ligand 1 ...
DECEMBER 15, 2017
The Case for TKI Monotherapy in mRCC
Tyrosine kinase inhibitor monotherapy still has a place in front-line therapy in patients with mRCC, according to a ...
NOVEMBER 28, 2017
Nivolumab Shows 3-Year Survival Benefit in Advanced RCC
Previously treated patients with advanced renal cell carcinoma (RCC) given nivolumab had improved survival at three ...
NOVEMBER 17, 2017